Neil Campbell
Overview
Neil Campbell is an experienced transactional attorney who counsels clients on an array of transactions relating to drug and medical device research, development, and manufacturing.
Career & Education
- Life Sciences Transactions Associate, AmLaw 50 firm
- Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the U.S., Europe, and Japan, in a broad range of life sciences transactional matters.
- Preclinical Imaging Shared Resource Manager, Rutgers Cancer Institute of New Jersey
- Life Sciences Transactions Associate, AmLaw 50 firm
- Rutgers Law School, J.D., cum laude
- University of Plymouth, MRes
- University of Plymouth, B.S.
- New Jersey
- New York
- Member, Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance
Neil's Insights
Client Alert | 3 min read | 11.20.25
Implications of CRISPR Dispute on Licensees
A decision in May from the Federal Circuit Court of Appeals has extended the long-standing and well-publicized dispute over inventorship of use of CRISPR-Cas9 technology in eukaryotic cells. When final resolution comes, it will have important implications for users of this technology. Companies currently licensing CRISPR-Cas9 from one of the two groups claiming ownership rights to the fundamental patents covering this technology and those considering licenses or investment in users of the technology should review existing or proposed licenses to better prepare for the potential outcomes of the dispute.
Representative Matters
Manufacturing and R&D Agreements
- Drafted and negotiated multiple complex development and manufacturing agreements for CAR-T product supply chain of a clinical-development stage company client.
- Represented early-stage drug development accelerator company in development and supply agreements for its gene therapy treatment for a rare genetic disorder.
- Drafted and negotiated sponsored research and other agreements with academic institutions in the U.S., EU, and UK.
- Provided strategic legal counseling to multiple drug development companies in connection with large, multicenter, global Phase 2 and 3 clinical studies for small molecule and biologic products.
Licensing and Collaboration Transactions
- Represented multiple early-stage, venture-backed drug development companies in research collaborations to discover and/or generate multi-specific or conjugated antibodies directed against designated drug targets.
- Represented pioneering biotechnology company in a collaboration and option-to-license agreement with global biopharmaceutical company to develop multi-specific biologics for multiple targets in oncology by leveraging the biotechnology company’s platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales.
- Represented Japanese biotechnology company in a strategic collaboration agreement with global biotechnology company, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING.
- Represented a biotechnology company developing next-generation cell therapies in a license and collaboration with a clinical-stage genome editing company to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920 million plus royalties.
- Represented a commercial-stage biotechnology company in a research and development collaboration to develop TCR-based immunotherapies for solid tumors, with an option to exclusively license candidates resulting from the collaboration.
- Represented a leading biotechnology company in a license agreement with Agios for novel siRNA for potential.
Neil's Insights
Client Alert | 3 min read | 11.20.25
Implications of CRISPR Dispute on Licensees
A decision in May from the Federal Circuit Court of Appeals has extended the long-standing and well-publicized dispute over inventorship of use of CRISPR-Cas9 technology in eukaryotic cells. When final resolution comes, it will have important implications for users of this technology. Companies currently licensing CRISPR-Cas9 from one of the two groups claiming ownership rights to the fundamental patents covering this technology and those considering licenses or investment in users of the technology should review existing or proposed licenses to better prepare for the potential outcomes of the dispute.
Neil's Insights
Client Alert | 3 min read | 11.20.25
Implications of CRISPR Dispute on Licensees
A decision in May from the Federal Circuit Court of Appeals has extended the long-standing and well-publicized dispute over inventorship of use of CRISPR-Cas9 technology in eukaryotic cells. When final resolution comes, it will have important implications for users of this technology. Companies currently licensing CRISPR-Cas9 from one of the two groups claiming ownership rights to the fundamental patents covering this technology and those considering licenses or investment in users of the technology should review existing or proposed licenses to better prepare for the potential outcomes of the dispute.
